Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval
ALK Class Highly Competitive
Executive Summary
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
You may also be interested in...
Natco And MSN Battle Chugai Over Alectinib In India
Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.
Chugai Pursues Alecensa Patent Infringement Charges In India
Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.
Yescarta Becomes Japan’s Second Approved CAR-T
Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing.